1. Differentiated Pipeline Strategy:
Focusing on frontier target discovery and molecular design as the core, we are building a pipeline centered on high-potency technology platforms including monoclonal antibodies, bispecific antibodies, and fusion proteins.
2. Clinical Value-Driven Approach:
Through project research, drug design, and translational medicine studies, we precisely address unmet medical needs.
3. Efficient R&D System:
We have established end-to-end capabilities spanning target validation, candidate screening, and preclinical development to accelerate the translation of innovative molecules from bench to bedside.
